• Home Study Details

  • Home / Learn / Home Study CE / Home Study Details


Breathe Easier: Exploring the Pharmacotherapy Advancements in Cystic Fibrosis Treatment

Program Type

Monograph

Credits

2 Contact Hour(s)

Release Date

Friday, August 17, 2018

Offline Date:

Monday, August 17, 2020

ACPE Expiration Date

Tuesday, August 17, 2021

Target Audience

Nurse, Pharmacist

Cost

$0.00

  • Overview

    Cystic fibrosis (CF) is a chronic progressive multi-organ disease prevalent worldwide varying by ethnic background. It is the most common life-shortening genetic disorder in North America, affecting 1 in 2000 Caucasian individuals. CF has autosomal recessive inheritance and is caused by a genetic mutation in a gene on chromosome 7 that encodes the cystic fibrosis transmembrane conductance regulator (CFTR) protein – a cyclic adenosine monophosphate (cAMP) regulated ion channel. Most patients diagnosed with CF have parents who do not have symptoms of CF but are heterozygote or carriers of the disease. As an autosomal recessive disease, patients need mutations in both CFTR alleles to develop CF and so it is equally common in both gender. 

    Rating


    Handouts

    Homestudy PDF:   18189H01.pdf

    Financial Support By

    Vertex Pharmaceuticals
  • Nurse

    Describe the epidemiology and basic pathophysiology of cystic fibrosis (CF) & the organs affected.
    Identify the principles of precision medicine in CF patients that are currently impacting clinical practice.
    Distinguish the requirements for patients who qualify for cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy.
    Analyze the improved disease progression in CF patients who have been initiated on CFTR modulation therapy.
    Employ best practices for patient counseling, as well as improving access and adherence to therapy.


    Pharmacist

    Describe the epidemiology and basic pathophysiology of cystic fibrosis (CF) & the organs affected.
    Identify the principles of precision medicine in CF patients that are currently impacting clinical practice.
    Distinguish the requirements for patients who qualify for cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy.
    Analyze the improved disease progression in CF patients who have been initiated on CFTR modulation therapy.
    Employ best practices for patient counseling, as well as improving access and adherence to therapy.

  • Activity Type

    Knowledge

    Universal Activity Number

    Nurse 0798-0000-18-189-H01-P

    Pharmacist 0798-0000-18-189-H01-P

    ACPE PharmCon, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

    PharmCon, Inc. is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

    In order to obtain a Statement of Credit, participants must score no less than a 70% on the activity's test and complete a program evaluation.

  • Faculty

    Priyam Mithawala, PharmD
    Assistant Professor of Pharmacy Practice, Presbyterian College School of Pharmacy




HARDWARE REQUIREMENTS
Standard Windows/Mac System
iPad or iPhone
Minimum screen resolution: 1024x768
Speakers or headphones
 
 


SOFTWARE REQUIREMENTS
Microsoft Edge
Internet Explorer 8.0 or higher
Google Chrome
Safari
Firefox 3.0.3 or higher
Adobe Acrobat Reader


NETWORK REQUIREMENTS
Broadband Internet Connection:
T1, Hi-speed DSL or Cable
4G cellular connection
 
 
 

This continuing education activity is held as copyright by PharmCon, Inc. Through this notice, PharmCon, Inc. grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

 

©2015 PharmCon, lnc. All Rights Reserved | Terms & Conditions | Privacy PolicyContinuing Education For Healthcare Professionals
Developed By: ITB, Inc.